title: Medical management of endometriosis: novel targets and approaches towards the development of future treatment regimes.
abstract: Endometriosis remains an enigmatic disease in women of reproductive age. Current treatment regimes used to manage the disease are primarily designed to induce a hypoestrogenic state which leads to a reduction in disease and associated symptoms. While these regimes have been used with great success, there are still drawbacks and limitations to these types of therapies. In this review, we address the shortcomings of current drugs used to medically manage endometriosis and offer potential target areas which may be attractive alternatives to current therapies. Emphasis is placed upon the promising research using tumor necrosis factor inhibitors in this context. Further, we discuss the advantages of such therapies and offer experimental approaches towards the development and testing of these regimes.
authors.affiliation: Department of Obstetrics and Gynecology, University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. wnothnic@kumc.edu
authors.forename: Warren B
authors.initials: WB
authors.lastname: Nothnick
authors.forename: Thomas M
authors.initials: TM
authors.lastname: D'Hooghe
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D011374:Progesterone / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D047072:Aromatase Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D011374:Progesterone